Uremic toxin and bone metabolism

Journal of Bone and Mineral Metabolism

Volumn 24, Issue 2, 2006, Pages 172-175

  Iwasaki, Yoshiko ^a   Yamato, Hideyuki ^b   Nii Kono, Tomoko ^c   Fujieda, Ayako ^b   Uchida, Motoyuki ^b   Hosokawa, Atsuko ^b   Motojima, Masaru ^d   Fukagawa, Masafumi ^c  

^a OITA UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Japan)

^b KUREHA CORPORATION   (Japan)

^c KOBE UNIVERSITY   (Japan)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN; TOXIN;

ADYNAMIC BONE DISEASE; BONE DISEASE; BONE METABOLISM; BONE TURNOVER; HUMAN; KIDNEY FAILURE; OSTEITIS FIBROSA; OSTEOMALACIA; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; UREMIA;

ALUMINUM; BONE AND BONES; BONE DISEASES; BONE RESORPTION; GLYCOPROTEINS; HUMANS; INDICAN; OSTEITIS FIBROSA CYSTICA; OSTEOPROTEGERIN; PARATHYROID HORMONE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RENAL OSTEODYSTROPHY; TOXINS, BIOLOGICAL; UREMIA; VITAMIN D;

EID: 33646486618     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-005-0667-7     Document Type: Review

References (33)

1. HH Malluche E Ritz HP Lange L Kutschera M Hodgson U Seiffert W Schoeppe 1976 Bone histology in incipient and advanced renal failure Kidney Int 9 355 362
2. DJ Sherrard G Hercz Y Pei NA Maloney C Greenwood A Manuel C Saiphoo SS Fenton GV Segre 1993 The spectrum of bone disease in end-stage renal failure - an evolving disorder Kidney Int 43 436 442
3. R Vanholder RD Smet G Glorieux A Argiles U Baurmeister P Brunet W Clark G Cohen PP De Deyn R Deppisch B Descamps-Latscha T Henle A Jorres HD Lemke ZA Massy J Passlick-Deetjen M Rodriguez B Stegmayr P Stenvinkel C Tetta C Wanner W Zidek European Uremic Toxin Work Group (EUTox) 2003 Review on uremic toxins: classification, concentration, and interindividual variability Kidney Int 63 1934 1943
4. R Vanholder G Glorieux RD Smet N Lameire for the European Uremic Toxin Work Group (EUTox) 2003 New insights into uremic toxins Kidney Int 84 S6 S10
5. DL Andress GA Howard RS Birnbaum 1991 Identification of low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma Kidney Int 39 942 945
6. S Disthabanchong H Hassan CL [tmp] McConkey KJ Martin EA Gonzalez 2004 Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells Kidney Int 65 897 903
7. SJ Steddon CW Mcintyre NJ Schrieder JM Burrin J Cunningham 2004 Impaired release of interleukin-6 from human osteoblastic cells in the uraemic milieu Nephrol Dial Transplant 19 3078 3083
8. MS Wangner S Stracke PM Jehle F Keller D Zellner DJ Baylink S Mohan 2000 Evaluation of IGF system component levels and mitogenic activity of uremic serum on normal human osteoblasts Nephron 84 158 166
9. G Hercz Y Pei C Greenwood A Manuel C Saiphoo WG Goodman GV Segre S Fenton DJ Sherrard 1993 Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function Kidney Int 44 860 866
10. Y Iwasaki-Ishizuka H Yamato T Nii-Kohno K Kurokawa M Fukagawa 2005 Down-regulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low-turnover bone Nephrol Dial Transplant 20 1904 1911
11. T Niwa N Takeda A Tatematsu K Maeda 1998 Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography Clin Chem 34 2264 2267
12. T Niwa T Nomura M Sugano T Kodama Y Uehara K Maeda 1991 Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats Nephron 57 84 88
13. T Niwa 2000 Uremic toxicity. Indoxyl sulfate SG Massry RJ Glassock Textbook of Nephrology 4th edn. Williams and Wilkins, Baltimore Lippincott 1269 1272
14. T Niwa I Aoyama F Takayama S Tsukushi T Miyazaki A Owada T Shigai 1999 Urinary indoxyl sulfate is a clinical factor that affects the progression of renal failure Miner Electrolyte Metab 25 118 122
15. Y Iwasaki-Ishizuka H Yamato T Nii-Kono K Kurokawa M Fukagawa 2003 Skeletal resistance to PTH is induced by indoxyl sulfate, one of the uremic toxins, leading to adynamic bone J Am Soc Nephrol 14 469 (abstract)
16. Y Iwasaki H Yamato T Takahashi K Ikeda T Kurosawa K Kurokawa M Fukagawa 2002 Renal dysfunction causes suppression of bone turnover in the absence of secondary hyperparathyroidism, leading to adynamic bone disease J Am Soc Nephrol 13 578 (abstract)
17. M Motojima A Hosokawa H Yamato T Muraki T Yoshioka 2002 Uremic toxins proximal tubular injury via organic anion transporter-1-mediated uptake Br J Pharmacol 135 555 563
18. A Enomoto M Takeda A Tojo T Sekine SO Cha S Khamdang F Takayama I Aoyama S Nakamura H Endou T Niwa 2002 Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity J Am Soc Nephrol 13 1711 1720
19. M Motojima A Hosokawa H Yamato T Muraki T Yoshioka 2003 Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kB and free radicals in proximal tubular cells Kidney Int 63 1671 1680
20. T Deguchi H Kusuhara A Takedate H Endou M Otagiri Y Sugiyama 2004 Characterization of uremic toxin transport by organic anion transporters in kidney Kidney Int 65 162 174
21. XC Bai D Lu J Bai H Zheng ZY Ke Li Xm SQ Luo 2004 Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappa B Biochem Biophys Res Commun 314 197 207
22. N Mody F Parhami TA Sarafian LL Demer 2001 Oxidative stress modulates osteoblastic differentiation of vascular and bone cells Free Radic Biol Med 31 509 519
23. 2-derived free radical-treated fibronectin substratum reduces the bone nodule formation of rat calvarial osteoblasts Mech Ageing Dev 98 113 125
24. JS Sun YH Tsuang WC Huang LT Chen YS Hang FJ Lu 1997 Menadione-induced cytotoxicity to rat osteoblasts Cell Mol Life Sci 53 967 976
25. H Yasuda N Shima N Nakagawa S Mochizuki K Yano N Fujise Y Sato M Goto K Yamaguchi M Kuriyama T Kanno A Murakami E Tsuda T Morinaga K Higashio 1998 Identification of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin: a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 1329 1337
26. WS Simonet DL Lacey CR Dunstan M Kelley MS Chang R Luthy HQ Nguyen S Wooden L Bennett T Boone G Shimamoto M DeRose R Elliott A Colombero HL Tan G Trail J Sullivan E Davy N Bucay L Renshaw-Gegg TM Hughes D Hill W Pattison P Campbell S Sander G Van J Tarpley P Derby R Lee WJ Boyle 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 309 319
27. H Yasuda N Shima N Nakagawa K Yamaguchi M Kinosaki S Mochizuki A Tomoyasu K Yano M Goto A Murakami E Tsuda T Morinaga K Higashio N Udagawa N Takahashi T Suda 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95 3597 3602
28. DL Lacey E Timms HL Tan MJ Kelley CR Dunstan T Burgess R Elliott A Colombero G Elliott S Scully H Hsu J Sullivan N Hawkins E Davy C Capparelli A Eli YX Qian S Kaufman I Sarosi V Shalhoub G Senaldi J Guo J Delaney WJ Boyle 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165 176
29. JJ Kazama T Shigematsu K Yano E Tsuda M Miura Y Iwasaki Y Kawaguchi F Gejyo K Kurokawa M Fukagawa 2002 Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure Am J Kidney Dis 39 525 532
30. G Coen P Ballanti A Balducci S Calabria F Stephanie L Jankovic M Manni M Moroseti E Moscaritolo D Sardella E Bonucci 2002 Serum osteoprotegerin and renal osteodystrophy Nephrol Dial Transplant 17 233 238
31. M Satoh H Hayashi M Watanabe K Ueda H Yamato T Yohioka M Motojima 2003 Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure Nephron Exp Nephrol 95 e111 118
32. T Niwa T Nomura S Sugiyama T Miyazaki S Tsukushi S Tsutsui 1997 The protein metabolite hypothesis: a model for the progression of renal failure. An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients Kidney Int 52 Suppl 62 S23 28
33. T Niwa M Ise 1994 Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis J Lab Clin Med 124 96 104